A 58-year-old African-American woman presents to the ER with episodic pressing/burning anterior chest pain that began two days earlier for the first time in her life. The pain started while she was walking, radiates to the back, and is accompanied by nausea, diaphoresis and mild dyspnea, but is not increased on inspiration. The latest episode of pain ended half an hour prior to her arrival. She is known to have hypertension and obesity. She denies smoking, diabetes, hypercholesterolemia, or a family history of heart disease. She currently takes no medications. Physical examination is normal. The EKG shows nonspecific changes.

eligible ages (years): 18.0-999.0,  All  Low Back Pain Must live in the United States Must understand and write English Must have access to a computer with e-mail and expect to have this access for at least 3 years Must be 18 years old Must have seen a doctor for back pain at least once in the past year  Pregnancy Back surgery in the past 6 months Expectation of having back surgery in the next 6 months Back pain due to a car accident or other major injury within the last 6 months Back pain or sciatica due to systemic disease (inflammatory rheumatic diseases, tumor, or other) Major physical or mental health condition for which one is currently being treated that severely limits daily activities Terminal illness Receiving disability or workers compensation insurance payments for back pain or sciatica Presently involved in legal proceedings because of back pain or sciatica Difficulty with bladder or bowel control that began with back pain or sciatica


eligible ages (years): 30.0-69.0,  All  Arrhythmia Cardiovascular Diseases Coronary Disease Death, Sudden, Cardiac Heart Diseases Myocardial Infarction Myocardial Ischemia Ventricular Fibrillation Men and women, ages 30 to 69. Documented myocardial infarction


eligible ages (years): 25.0-49.0,  All  Cardiovascular Diseases Heart Diseases Hypertension Obesity Vascular Diseases Men and women, ages 25 to 49. Diastolic blood pressure between 78 and 89 mm Hg. Free of major disease. Not on a special diet or antihypertensive medication at entry. Some mild to moderately obese subjects


eligible ages (years): 18.0-65.0,  All  Cardiovascular Diabetes Obesity Hypertension Ethnicity: African Americans To enroll participants must self-identify as African Americans and be born in the United States, with American born parents or be born in Africa with African born parents. In the future, we plan to expand the study to other groups which self-identify as African Americans (i.e. AfroCarribeans and Hispanic blacks) Age: The age range of the participants will be between 18 and 50 years Medical History: To participate in the study subjects should identify themselves as healthy Menstrual History: Women must give a history of regular monthly cycles (24-35 days) for at least one year  African American Ethnicity other than American or West African ancestry. In the future, we will expand the study to other African American groups such as individuals of Afro-Caribbean and Hispanic blacks Medications: People who take medications that are known to alter the parameters which are under investigation in this study will be excluded. An example would be medications used to treat hyperlipidemia such as statins, niacin, bile acid sequestrants and fibric acid derivatives. Subjects on thyroid hormone replacement will be included if their TSH is normal Diabetes: Because diabetes affects insulin sensitivity and TG levels all people with diabetes even if the diabetes is controlled with diet alone will not be enrolled in the study Breastfeeding: Women who are breastfeeding or have an infant that is less than four months of age will be excluded. This is because the physiologic changes associated with breastfeeding or recent childbirth affect the parameters under study Menstrual History: Women with a history of irregular menstrual cycles in the year prior to the study will be excluded. Due to the requirement for regular menses, women in the following categories, regardless of age will be excluded: history of hysterectomy, history of bilateral oophorectomy, use of Norplant or Depo-Provera for contraception History of bleeding diathesis


eligible ages (years): 29.0-85.0,  All  Stroke Cerebral Infarction African Americans are eligible if they had a non-cardioembolic ischemic stroke at lease 7 days, but no more than 90 days before entering the trial African American 85 years of age Non-cardioembolic cerebral infarct Onset of entry stroke at least 7 days but no more than 90 days CT or MRI following entry stroke and consistent with occurrence of entry stroke (i.e., shows entry infarct, shows old infarct, or shows no infarct) Measurable neurologic deficit that correlates with onset of entry stroke Informed consent Able to follow outpatient treatment program  Volunteers with transient ischemic attack (TIA) as the potentially qualifying event, intracranial hemorrhage, nonatherosclerotic stroke, sensitivity or major allergy to the study drugs, Modified Barthel Index < 10 or childbearing potential are not eligible Non-qualifying entry events: TIA, subarachnoid hemorrhage, cardiac embolism, iatrogenic stroke, postoperative stroke within 30 days of operation, and carotid endarterectomy as preventive treatment of entry stroke Mean arterial blood pressure > 130mmHg on 3 consecutive days Modified Barthel Index < 10 History of dementia or neurodegenerative disease Severe comorbid condition such as cancer that would limit survival during 2 year follow-up period Concurrent enrollment in another clinical trial Sensitivity or allergy to aspirin or ticlopidine Women of childbearing potential Peptic ulcer disease, active bleeding diathesis, lower gastrointestinal bleeding, platelet or other hematologic abnormality currently active or clinically active in the past year, hematuria, positive stool guaiac, prolonged PT or PTT, BUN > 40mg%, serum creatinine > 2.0mg%, thrombocytopenia or neutropenia as defined by the lower limit of normal for the platelet count or white blood cell count, respectively (absolute neutrophil count of > 1800/mm3 required for participation), or > 2 times the upper range of normal on liver function tests (SGOT, SGPT, total bilirubin)


eligible ages (years): 0.0-999.0,  All  Cardiovascular Diseases Coronary Disease Hypertension Heart Diseases


eligible ages (years): 35.0-84.0,  All  Cardiovascular Diseases Heart Diseases Atherosclerosis Coronary Disease Hypertension Cerebrovascular Disorders African American


eligible ages (years): 0.0-999.0,  All  Cardiovascular Diseases Heart Diseases Hypertension


eligible ages (years): 18.0-999.0,  All  Heart Failure, Congestive In order to be considered an eligible subject, all of the following entry must be met Subjects must be competent to provide informed written consent. Subjects must sign an IRB/IEC approved informed consent form prior to the initiation of any study procedures Subjects must be 18 years of age or older Subjects must have ischemic or nonischemic cardiomyopathy with symptoms of NYHA Class III or IV chronic heart failure Subjects must have a LVEF of less than or equal to 35%, measured within 60 days of the Screening Visit. LVEF must be assessed by radionuclide ventriculography (MUGA). If the subject has experienced any cardiovascular events, has undergone any interventions, or received any changes in treatment that may have affected LV function since the most recent EF measurement, an LVEF measurement must be completed prior to the subject being randomized Subjects must have a left ventricular end diastolic dimension (LVEDD) of >2.7 cm/m2 as measured by 2-D ECHO within 12 months of the Screening Visit Subjects must be on optimal conventional heart failure therapy (with the exception of a beta-blocker), including an ACEI for at least 30 days prior to the Screening Visit, or the subject must have had a trial of an ACEI and proven to be intolerant, or the subject must be taking an ARB for at least 30 days prior to the Screening Visit or proved to be intolerant. Optimal conventional therapy may also spironolactone, digitalis glycosides, diuretics, or other vasodilators Subjects must have failed the initiation, or the up-titration, of a beta-blocker drug due to hemodynamic intolerance within 12 months prior to the Screening Visit. Failure to tolerate beta-blockade for hemodynamic reasons is defined as worsening signs and symptoms of chronic heart failure, hypotension accompanied with symptoms, or evidence of organ hypoperfusion, which in the judgment of the treating physician precluded further treatment with the beta-blocker. This beta-blocker intolerance must have been documented prior to Screening, and a narrative description of the intolerance must be approved by Myogen prior to Randomization  Subjects who meet any one of the following will be deemed ineligible for participation in the study Subjects with CHF due to or associated with uncorrected primary valvular disease, uncorrected thyroid disease, obstructive/hypertrophic cardiomyopathy, pericardial disease, amyloidosis, active myocarditis, malfunctioning artificial heart valve, uncorrected congenital heart disease, isolated right-sided heart failure, or primary pulmonary hypertension Subjects who have undergone a cardiac revascularization, valvular surgery, or bi-ventricular resynchronization procedure within 60 days prior to the Screening Visit Subjects listed for heart transplantation who are expected to be transplanted within 6 months of randomization Subjects who have had a myocardial infarction within 90 days prior to the Screening Visit Subjects with an ECG recorded at the Screening Visit showing any of the following: 1) evidence of transmural ischemia (dynamic ST elevation or ST elevation associated with ischemic symptoms), or 2) ventricular tachycardia (VT) or premature ventricular complexes (PVCs) associated with symptoms, or 3) VT of greater than or equal to 6 beats Subjects with sustained (>15 seconds) VT, unless precipitated by an event such as an acute myocardial infarction, induction by catheter placement, or by an electrophysiology procedure, or addressed by AICD placement Subjects with an AICD that has fired for any ventricular arrhythmia within 90 days of the Randomization Visit Subjects with a documented diagnosis of angina that meets either of the following 1) angina diagnosed as unstable at any time within the 60 days prior to the Screening Visit or 2) angina is the primary symptom that limits daily physical activity Subjects who have had ventricular reduction surgery or cardiac myoplasty


eligible ages (years): 18.0-80.0,  All  Back Pain Chronic back pain for at least 6 months Treatment by medication or physical therapy  Acute or life threatening physical illness Current alcohol or substance abuse or dependence Current psychosis or suicidal ideation treatment by anesthesiology, chiropractic care or surgery


eligible ages (years): 18.0-90.0,  All  Kidney Failure, Chronic End-stage renal disease Hemodialysis Hypertension Written informed consent  Hypotension of less than 90 mmHg systolic High-grade aortic stenosis Heart failure of NYHA stage III and IV Acute myocardial infarction (within the last 4 weeks) Acute heart failure Known allergy to the medicament amlodipine or other constituents of the medicament Severe disorders of liver function Pregnancy and breast-feeding


eligible ages (years): 30.0-75.0,  All  Hypertension Type 2 Diabetes Mellitus Clinical diagnosis of hypertension Clinical diagnosis of type 2 diabetes or impaired glucose tolerance  History of congestive heart failure, myocardial infarction, or coronary revascularization in the recent 6 months Taking calcium channel blocker for the purpose of angina pectoris Reduced ejection fraction (< 40%) Second or third-degree of atrioventricular block Severe hypertension (> 200/110 mmHg) or secondary hypertension History of stroke in the recent 6 months Serum creatinine > 2.5 mg/dl Estimated survival duration less than 3 years due to other conditions Pregnant woman or possibly pregnant woman


eligible ages (years): 65.0-84.0,  All  Hypertension Cardiovascular Diseases Outpatients aged 65 years or older, and less than 85 years (at the time of informed consent), regardless of sex Current antihypertensive treatment with monotherapy SBP ≥ 140mmHg or DBP ≥ 90mmHg in a sitting position on two measurements on two clinic visits At least one of the following risk factors Diabetes mellitus Type 2 History of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemic attack (more than 6 months before giving informed consent) Diagnosis of asymptomatic cerebrovascular disease History of myocardial infarction (more than 6 months before giving informed consent) Diagnosis of angina pectoris or heart failure (New York Heart Association [NYHA] functional classification I or II) Diagnosis of left ventricular hypertrophy (thickness of the wall of interventricular septum ≥ 12mm on echocardiography or Sv1+Rv5 ≥ 35mm on electrocardiography before informed consent)  Secondary hypertension or malignant hypertension Heart failure (NYHA functional classification III or IV) Required treatment for malignant tumor Serious liver or renal dysfunction (serum creatinine > 2.5mg/dL or with dialysis treatment) Not appropriate for change to the test drugs from current therapy for hypertension or coronary diseases (i.e. calcium channel blockers, β-blockers, thiazide diuretics, etc.) History of serious adverse drug reactions to angiotensin II receptor blockers or calcium channel blockers Patients with other serious reasons (i.e. illness, significant abnormalities, etc.) that investigators judge inappropriate for the study


eligible ages (years): 18.0-70.0,  All  Hypertension Essential Hypertension SBP 140-159 mmHg DBP 90-99 mmHg  Intolerance of or allergy to ACE Inhibitors or ARBS Pregnant or Breastfeeding Pre-menopausal women Uncontrolled cardiac or renal failure Diabetes mellitus


eligible ages (years): 18.0-999.0,  All  Myocardial Ischemia Outpatients > =18 years of age with diagnosed clinically stable angina pectoris  Patients with congestive heart failure, clinically significant cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG


eligible ages (years): 20.0-79.0,  All  Hypertension Ischemic Heart Disease Congestive Heart Failure Stroke Clinical diagnosis of hypertension Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (IHD) or cerebrovascular disease, obesity (BMI>25), chronic heart failure (NYHA II-III), and electrocardiogram (ECG) abnormality (LVH)  Patients who have already been administered ARB Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and who are stable but are going to implement PCI or coronary artery bypass grafting(CABG) Severe/malignant/secondary hypertensive patients Pregnant women and women of childbearing potential History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG within the preceding 6 months Arrhythmia needed to be treated or accompanied with symptoms, second or third degree AV block Severe renal impairment (Serum creatinine >3.0 mg/dl) Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)


eligible ages (years): 18.0-76.0,  All  Diabetes History of diabetes for at least 5 years, with a least 2 risk factors (i.e. hypertension, elevated cholesterol levels, history of or current smoker, obese, family history of heart disease) & atypical chest pain  Typical chest pain being treated with medication, unable to exercise, previous confirmed heart disease


eligible ages (years): 8.0-18.0,  All  Chest Pain 18 years of age Pediatric patients with referrals for innocent heart murmurs Pediatric patients experiencing chest pain English speaking  Non English speaking patients


eligible ages (years): 50.0-999.0,  All  Coronary Disease Ischemic Heart Disease Heart Failure Patients with HF or IHD who are not currently taking the study medications of interest (ACE inhibitors/angiotensin receptor blockers for HF or statins for IHD) and whose primary care physicians are part of the study population  Patients who are unable or unwilling to give informed consent previously taken the study medications according to dispensing records allergy or intolerance to study medications residents of long-term care facilities unable to confirm a diagnosis of either HF or IHD primary care physician has already contributed 5 patients to the study


eligible ages (years): 18.0-999.0,  All  Hypertension Greater than 18 years of age Patients with high blood pressure  Hypertensive encephalopathy, stroke or transient ischemic attack within the past 6 months History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months Type 1 diabetes mellitus


eligible ages (years): 20.0-75.0,  All  Breast Cancer Neoplasm Metastasis Hormonal therapy-resistant MBC ER (-), failure of hormonal therapy for MBC, or relapse within 6 months after adjuvant hormonal therapy No anthracyclines for MBC and no prior taxanes At least 6 months from the completion of adjuvant chemotherapy Measurable or evaluable lesions Age: 20 to 75 years PS: 0-3 WBC >= 4,000 /mm3 or ANC >=1,000 /mm3, Platelet >= 100,000 /mm3, SGOT/SGPT <= 1.5 x ULN, T-Bil <= 1.5 mg/dL, Cr <= 1.5 mg/dL normal ECG Written informed consent  pregnant malignant pleural effusion, ascites, or pericardial effusion that requires emergent treatment Active infection other cancer present within the last 5 years previous stem cell transplantation brain metastasis that requires emergent treatment relapse within 6 months after completion anthracycline or during anthracycline more than 250mg/m2 of anthracyclines hypersensitivity of drug interstitial pneumonitis or pulmonary fibrosis


eligible ages (years): 18.0-75.0,  All  Angina Pectoris Chronic stable angina pectoris Documented coronary artery disease Previous treatment with atenolol or other beta-blocker agent Exercise tolerance test positivity and stability  Heart rate < 60 bpm Congestive heart failure


eligible ages (years): 18.0-999.0,  All  Angina Pectoris Metabolic Syndrome X Chronic stable angina to see if this improves Previous positive exercise tolerance test to ensure that repeating it yields a result Disease not suitable for coronary intervention (Coronary artery bypass grafting or angioplasty) so that best routine care is not withheld Do not have overt diabetes work on this is being undertaken elsewhere Body mass index (BMI) greater than 25  Diabetes mellitus see above Liver failure (ALT>70U/l, AST>80U/l) Renal failure (creatinine > 130mmol/l) Cardiac failure rosiglitazone is contraindicated in those with NYHA 3 and 4 cardiac failure Physical disability if it precludes treadmill testing Women of child bearing capacity Breast feeding mothers


eligible ages (years): 50.0-999.0,  All  Osteoporosis Women aged 50 and older Lumbar spine BMD (L1 to L4) T score between 0 and -2.0 At least 3 years postmenopausal  Prior low trauma hip or vertebral fracture Total hip or femoral neck T score of <-2.0 Bone disorders other than osteopenia (e.g., hyperparathyroidism or Paget's disease) Treatment within six months of study entry with androgen, calcitonin, estrogen, progesterone, fluoride in a tablet form, raloxifene, tamoxifen, etidronate, prednisone or an equivalent at 5 mg/d for 12 months or greater, lithium or anticonvulsants Alendronate or risedronate use for at least four weeks, within the last three years Current treatment with nitrates Systolic blood pressure of =<100 mm Hg or diastolic blood pressure >=100 mm Hg at the baseline screening examination Abnormal electrocardiogram (ECG) at the baseline screening examination history of myocardial infarction, angina, valvular or congenital heart disease Disabling conditions that may interfere with follow-up visits


eligible ages (years): 21.0-55.0,  All  Low Back Pain Age 21 to 55 Idiopathic mechanical low back pain (LBP) matching classification 1-4 of the Quebec Task Force LBP classified as subacute (onset 4-12 weeks previous) or chronic (onset more than 12 weeks previous), with the current episode occurring at least four weeks prior to the date of contact with the clinic: In order to the greatest proportion of LBP patients that have a favorable natural history of improvement Written Informed Consent A minimum baseline score on the Roland Morris Disability Questionnaire (RMQ) of 6 points  LBP from other somatic tissues as determined by history, examination, and course (e.g. pain referred from visceral conditions) LBP diagnosis not meeting Classifications 1 through 4 of the Quebec Task Force, especially the following: low back pain associated with frank radiculopathy defined as typical shooting leg pain; positive straight leg-raising test; an altered lower extremity reflex; a dermatomal sensory deficit; at least one of the following: progressive unilateral muscle weakness or motor loss, or symptoms of cauda equina compression; and CT or MRI evidence of related anatomical pathology (e.g. abnormal disc, stenosis) Co-morbid pathology or poor health conditions in patients; Co-morbid conditions and general poor health significantly complicate the prognosis of LBP, and inject a variety of uncontrollable factors in case-management, not to mention experimental analysis and interpretation. Patients who have case histories and physical examination findings indicating other that average good health will be excluded from the study Bone and joint pathology contraindicating patient for SM of the lumbar spine and pelvis: Patients with spinal fractures, tumors, infections, arthropathies, and significant osteoporosis will be referred to appropriate health care Other contraindications for SM of the lumbar spine and pelvis (e.g. bleeding disorders or anticoagulant therapy, extreme obesity) Retention of legal advice related to this or a previous LBP episode: Patients with occupational or personal injuries will not be automatically excluded from the study unless they answer yes to a specific question about the retention of legal advice with respect to their LBP episode at the baseline interview Pregnancy: Pregnancy is a contraindication for exposing a patient to ionizing radiation and is a confounding factor in the usual course of LBP Inability to read or verbally comprehend English Clear evidence of narcotic or other drug abuse as determined by history and examination: injects significant confounding factors with respect to internal validity and feasibility Major clinical depression: Patients with scores greater than 17 on the Beck Depression Inventory will be excluded from the study. Patients with evidence of other psychiatric disorders as determined by history and exam will also be excluded


eligible ages (years): 18.0-999.0,  All  Unstable Angina Myocardial Infarction Age > 18 years or older Admission to the ICCU with ACS (non-ST elevation acute coronary syndrome or 24 hours after ST elevation myocardial infarction)  Presence of ischemic symptoms (≥5 minutes) during hospitalization Pain assessment of 3 out of 10 on Visual Analog Scale (VAS) 1 or dynamic ECG findings (ST segment deviation ≥0.05 mV or T wave inversion ≥ 0.3 mV) Willing and able to provide written informed consent according to the regulations of the Ministry of Health and the Helsinki committee instructions  Patient who meet any of the following are excluded from the study Persistent ST-segment elevation ≥ 1 mV in 2 or more contiguous leads or new LBBB Acute pulmonary edema Sepsis Sustained systolic blood pressure < 90 mm Hg or evidence of cardiogenic shock Pregnant women Use at randomization of agents known to enhance the efficacy of nitrates Clinically significant aortic stenosis Cr > 2 mg/dL Participation in another trial of an investigational drug or device on randomization


eligible ages (years): 18.0-999.0,  All  Chronic Thromboembolic Pulmonary Hypertension Diagnosis of CTEPH and patient consent  No patient consent


eligible ages (years): 21.0-69.0,  All  Obesity Participating in the BWHS study Residing in New York, Los Angeles, or Chicago


eligible ages (years): 18.0-75.0,  All  Non-Cardiac Chest Pain Undiagnosed Chest Pain Musculoskeletal Chest Pain Ischemic Heart Disease Acute episode of chest pain of less than 7 days duration as primary reason for admission to a chest pain clinic Admitted to a chest pain clinic, suspected of acute coronary infarction, but with a negative diagnosis confirmed by normal coronary enzymes and normal ECG Pain arising from the thorax and/or neck Able to read and understand Danish  Acute coronary syndrome Percutaneous Coronary Intervention Coronary Artery Bypass Grafting Other disease, diagnosed during this admission, which is likely to have caused the acute episode of chest pain No written consent Inflammatory joint disease Diabetes mellitus, type I Fibromyalgia Sharp trauma to the chest Malignant disease


eligible ages (years): 0.0-60.0,  All  Prader-Willi Syndrome Obesity Individuals enrolling in the Prader-Willi syndrome group will have a confirmed diagnosis of Prader-Willi syndrome, as confirmed by molecular and cytogenetic testing Individuals enrolling in the Early-onset Morbid Obesity group will have a documented medical history of their weight exceeding 150% of the ideal body weight or a body mass index greater than 97% before the age of 4 years; they will also be under the age of 30 years  Known genetic, chromosomal, or hormonal cause of cognitive impairment other than Prader-Willi syndrome


eligible ages (years): 10.0-999.0,  All  Supraventricular Tachycardia More than 10 years old Electrocardiographic diagnosis of SVT SVT not converted by the vagal manoeuvres  Signs of impaired cerebral perfusion Signs of pulmonary oedema Subsequent diagnosis of other types of arrythmias rather than SVT pregnancy by history


eligible ages (years): 15.0-40.0,  All  Pneumothorax Male or female Age between 15 and 40 years old First episode of spontaneous pneumothorax Symptomatic (dyspnea or chest pain) or the rim of air is > 2cm on CXR requiring simple aspiration Complete or nearly complete and persistent lung expansion immediately following manual aspiration Organ Function Requirements Adequate hematological function (Hb > 10 g/dl, ANC > 1.5 x 109/L, platelets > 100 x 109/L) Normal renal and hepatic functions: serum creatinine < 1 x ULN, SGPT and SGOT< 2.5 x ULN, alkaline phosphatase < 5 x ULN Written inform consent  With underlying pulmonary disease (asthma, chronic obstructive pulmonary disease, bronchiectasis, etc) With hemothorax or tension pneumothorax requiring chest tube insertion or operation A history of previous pneumothorax A history of previous ipsilateral thoracic operation Allergy to tetracycline or minocycline Pregnant or lactating patients Other serious concomitant illness or medical conditions Congestive heart failure or unstable angina pectoris History of myocardial infarction within 1 year prior to the study entry Uncontrolled hypertension or arrhythmia


eligible ages (years): 18.0-999.0,  All  Pulmonary Hypertension Must have completed Visit 14/Week 24 of the NCT00046319 study Women of childbearing potential must have a negative urine pregnancy test at the Screening/Enrollment Visit and agree to use a reliable double barrier method of contraception until study completion and for >=4 weeks following their final study visit Must have completed the Down-titration Period of NCT00046319 prior to enrollment in AMB-220-E and will meet the following additional Subjects with a diagnosis of HIV must have stable disease status at the time of Screening/Enrollment Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening Visit  Chronic prostanoid therapy, or other investigational prostacyclin derivative within 4 weeks prior to the Screening Visit Intravenous inotrope use within 2 weeks prior to the Screening Visit Females who are pregnant or breastfeeding Contraindication to treatment with an endothelin receptor antagonist (ERA)


eligible ages (years): 65.0-84.0,  All  Hypertension Cardiovascular Disease Diabetes Outpatients aged 65 years or older, and less than 85 years (at the time of informed consent), regardless of sex Systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg in a sitting position on two consecutive measurements at clinic during use of 1 or more antihypertensive medications Systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥100 mmHg in a sitting position on two consecutive measurements at clinic without antihypertensive medication Require at least one of the following medical history or risk factors Medical history Cerebrovascular accident: cerebral infarction, brain hemorrhage, subarachnoid hemorrhage（6 months or more prior to registration） Myocardial infarction, coronary revascularization (PCI or CABG) （6 months or more prior to registration） Angina pectoris (except for the patients having history of hospitalization within 6 months prior to registration) Risk factors Male  Secondary hypertension or malignant hypertension History of cerebrovascular accident (including TIA) or myocardial infarction within 6 months before registration Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) done within 6 months before registration or scheduled History of hospitalization for angina pectoris or heart failure within 6 months before registration Severe heart failure (New York Heart Association [NYHA] functional class III or more severe) Complications of atrial fibrillation, atrial flutter or severe arrhythmia Severe hepatic or renal dysfunction (including current treatment of dialysis or renal dysfunction with serum creatinine ≥ 2.0mg/dL) Not appropriate for change to the study drugs from current therapy for concurrent disease including coronary diseases (i.e. calcium channel blockers, diuretics, etc) History of serious side effect from study drugs (AT1 subtype angiotensin II receptor antagonist, calcium channel blocker, diuretic) Life threatening condition (malignant tumor, etc)


eligible ages (years): 18.0-75.0,  All  Musculoskeletal Chest Pain Non-cardiac Chest Pain Undiagnosed Chest Pain To be included in the project the participant must Have chest pain as their primary complaint Have an acute episode of pain of less than 7 days duration before admission Consent to the standardized evaluation program at the chest pain clinic Have pain the in the thorax and/or neck Be able to read and understand Danish. Be between 18 and 75 year of age Be a resident of the Funen County Patients will not be included if any of the following conditions are present ACS Have had Percutaneous Coronary Intervention (PCI) or Coronary Artery By-pass Grafting (CABG)  Participants will be excluded following baseline evaluation if any of the following conditions are present Pain not related to the joints and muscles of the neck and/or thorax (CTA negative, see below) New incidence of any of the above mentioned conditions/pathologies


eligible ages (years): 30.0-80.0,  All  Angina Pectoris Male Stable angina with one of Classical history of exertional angina pectoris Previous diagnostic exercise test Angiographic evidence of CAD Aged 30 to 80 years Weight between 60 and 100 Kg  Regular treatment with long-acting nitrates or nicorandil where these cannot be withdrawn 72 hours prior to the study Myocardial infarction, unstable angina, stroke or transient cerebral ischaemia within 3 months Systolic BP > 170 mmHg or diastolic BP > 100 mmHg Systolic BP < 100 mmHg or diastolic BP < 60 mmHg Orthostatic hypotension (> 20 mmHg fall in systolic BP on standing) Diabetes treated with oral hypoglycaemic agents or insulin Any clinically significant disease other than stable angina, excepting other cardiovascular disease risk factors, e.g. smoking, hypercholesterolaemia and diet-controlled diabetes Taking any drug that interacts with sildenafil Evidence of drug abuse


eligible ages (years): 20.0-999.0,  All  Neoplasms, Gastrointestinal Tract Specific Information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the investigational product that may impact subject is provided in the Investigator's Brochure (IB) Pilot Part Subjects eligible for enrollment in the Pilot Part of the study must meet all of the following Signed informed consent Male or female; ≥ 20 years (at the time of giving consent) Any histologically or cytologically confirmed gastric carcinoma independent of tumor ErbB2 status Subjects who have received one prior regimen for gastric carcinoma and developed disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine and/or cisplatin Left ventricular ejection fraction (LVEF) within institutional range of normal as measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive (LVEF of ≥50% required if normal range of LVEF is not provided by institution) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Able to swallow and retain oral medication Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study  Subjects meeting any of the following must not be enrolled in the study Pregnant or lactating female at anytime during the study Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatment Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2) Peripheral neuropathy of Grade 2 or greater Malabsorption syndrome, disease significantly affecting gastrointestinal function. Subjects with ulcerative colitis and Crohn's disease are also excluded History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety Life threatening infection Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent


eligible ages (years): 30.0-999.0,  All  Chest Pain At least one modifiable cardiovascular risk factor (smoking, hyperlipidemia, hypertension, diabetes mellitus, obesity)  Patients who "rule-in" for myocardial ischemia at initial testing Terminally ill (expected to survive less than 3 months) Unavailable for 6-month follow-up Cannot be contacted by telephone Institutionalized persons (prisoners, nursing home residents) Unable to provide informed consent (impaired mental status, unable to speak English)


eligible ages (years): 0.0-999.0,  All  Hodgkin's Disease Biopsy-proven HL Participation in IRB-approved protocols for the first-line treatment of HL between 1975-2000 (IRB #75-104, #75-103, #79-17, #81-103, #90-44, #91-69) English speaking


eligible ages (years): 18.0-65.0,  All  Anxiety/Depression in Cardiological Unit investigated for chest pain or palpitation 6 month ago at Cardiological Out-patient Clinic, Molde Hospital suffer of chest pain or palpitations  do not speak norwegian properly mentally retarded psychosis last 6 month current alcohol or drug misuse


eligible ages (years): 18.0-80.0,  All  Active Digital Ulcers Digital gangrene, ulcers in patients with severe secondary Raynaud`s phenomenon Stable therapy with vasoactive drugs, such as calcium channel blockers, angiotensin inhibitors/AT II receptor antagonists or pentoxifyllin 4 weeks before and during the treatment with sildenafil Unchanged immunosuppressive therapy 3 months before treatment with sildenafil No effect of prostacyclin treatment, contraindications for prostacyclins, or other reasons excluding this therapy  Therapy with iloprost during the last 4 weeks Sympathectomy during the last 4 weeks TIA, stroke, myocardial infarction during the last 6 months Instable angina pectoris Hemorrhagic diathesis, thrombocytic dysfunction, fibromuscular dysplasia Microangiopathic hemolytic anaemia Azotaemia Hypertonus not adjustable with diuretic, clonidine, ACE inhibitors/AT II antagonists, calcium channel blockers) Left ventricular ejection fraction< 20% Hypotonus < 80/40 mm Hg


eligible ages (years): 18.0-999.0,  All  Metastatic Cancer Diagnosis of malignant pleural effusion requiring pleurodesis confirmed by 1 of the following Histologically proven pleural malignancy Typical features of pleural malignancy seen on direct vision during thoracoscopy Pleural effusion in the context of histologically proven cancer elsewhere No primary lymphoma or small cell lung carcinoma All patients undergoing thoracoscopy for suspected malignant pleural effusion are eligible Life expectancy > 1 month Not pregnant or nursing No history of GI bleeding or untreated peptic ulceration No known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), opiates, or paracetamol


eligible ages (years): 18.0-999.0,  All  Cardiovascular Disease Men and women admitted for an IHD event (acute coronary syndrome or revascularization procedure) who are at low or moderate risk.91 Regular Internet access (home, work or other environment) Over 18 years of age Permission of the attending physician Able to read, write and understand English without difficulty No physical limitations to regular activity  Previous experience with a cardiac rehabilitation program Patients with depression, uncontrolled diabetes and other significant co-morbidities that may interfere with effective IHD management Those patients, who in the mind of the attending physician, are unsuitable for participation Those unable to provide informed consent Pregnant women High-risk patients for safety considerations (future studies will high-risk patients)


eligible ages (years): 18.0-999.0,  All  Type 2 Diabetes New onset of Type 2 Diabetes BMI>25kg/m2  Antiobesity, oral hypoglycaemic medications or any other prescription medications that may interfere with the study results Pregnancy Unable to converse competently in English as special arrangements would need to be made for such people and this would be impractical in a group setting Attending another weight management programme Patients who would be unable to attend all the programme sessions for medical or other reasons Any patients from groups listed in A24


eligible ages (years): 0.0-999.0,  All  Breast Neoplasm Patients with metastatic breast cancer  History of hypersensitivity to Caelyx or its components Women who are pregnant or breast-feeding Patients with severe myelosuppression


eligible ages (years): 40.0-999.0,  All  Chronic Obstructive Pulmonary Disease Clinical diagnosis of COPD > 40 years of age > 15 pack year smoking history  Contra-indication to beta-blocker use Severe COPD FEV1 < 30% or 1 L Not responsive the methacholine


eligible ages (years): 20.0-55.0,  All  Low Back Pain Patients with low back pain between 20 and 55 years old, submitted to a physical therapy treatment  Patients with no miofascial low back pain


eligible ages (years): 18.0-50.0,  All  HIV Current substance abuse Current high-risk sexual behavior African American racial identification  Non resident of Miami-Dade county


eligible ages (years): 18.0-80.0,  All  Angina Pectoris Patient must be between the ages of 18 and 80 years Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator's opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study Evidence of coronary artery disease that consists of a well-documented medical history (over 3 months prior to the enrollment) of myocardial infarction or significant coronary artery disease with noninvasive or angiographic confirmation Symptoms that support the diagnosis of chronic angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph (ECG) changes Moderate angina pectoris (Class II or Class III, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System) Naive patient or patient who's Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0 All anti-angina regimen (except short-acting nitroglycerin, and one beta-blocker or calcium channel blocker), warfarin or other oral anticoagulants which were used prior to this initial visit can be discontinued Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the verbal rating scales and diary cards Patient must be able to give voluntary written informed consent  With contraindication to perform treadmill Exercise Tolerance Test (ETT) Pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could interfere with exercise electrocardiograph interpretation Clinically significant arrhythmias or atrioventricular conduction block greater than first degree Clinically significant co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, history of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication History of congestive heart failure, unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry History of bleeding diathesis, or is on warfarin Implanted pacemaker Aspirin and/or statins started less than 14 days prior to the signing of informed consent Pregnancy or lactation Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and allow only short-acting nitroglycerin and one beta-blocker or calcium channel blocker


eligible ages (years): 0.0-999.0,  All  Heart Failure Patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction ≤40%), were >18 years of age, and were on stable optimal medical heart failure therapy excluding the use of beta-blockers within the previous 30 days   Patients were excluded for active viral myocarditis; hemodynamically significant valvular heart disease; hypertrophic cardiomyopathy, peripartum cardiomyopathy; contra-indications to beta-blockers (asthma or obstructive airway disease requiring scheduled bronchodilators or inhaled steroids), resting heart rate <55; supine blood pressure <85/50; second or third degree heart block); concomitant use of beta-agonists, beta-antagonists, or anti-arrhythmics; unstable angina; myocardial infarction or bypass surgery within 3 months; or significant renal insufficiency (creatinine >2.5 mg/dL), liver disease (transaminase levels > 3 fold above laboratory normal), or anemia


eligible ages (years): 18.0-65.0,  All  Obesity, Morbid Ischemic Heart Disease Morbidly obese patients who fulfill the NIH for surgical intervention  Patients deemed unfit for surgery Pregnant women, or who are attempting conception Subjects with any history of myocardial infarction, coronary artery bypass grafting surgery, coronary angiography with angioplasty and/or stenting, or any lesion > 50% of the coronary artery luminal diameter, cerebrovascular accident, or peripheral vascular disease with abnormal electrocardiograms and/or echocardiography History of drug or alcohol abuse Chronic liver disease


eligible ages (years): 18.0-75.0,  All  Adipose Tissue Lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance Obese (BMI >30 kg/m2) subjects also with normal glucose tolerance Obese with impaired glucose tolerance Obese with diet controlled diabetes mellitus Morbid obesity, type diabetes and post bariatric surgery (study part 2)  History of severe cardiac, hepatic or renal disease Thyroid dysfunction (hyper-or hypothyroidism), or other endocrine disturbance (acromegaly, growth hormone deficiency, hypoadrenalism or cortisol overproduction) Current malignant disease Known alcohol misuse Major psychiatric disease (including current use of antidepressants) History of major eating disorder (anorexia or bulimia nervosa)


eligible ages (years): 0.0-999.0,  All  Heart Failure Randomised control trials of beta-blocker versus control in patients with documented heart failure Unconfounded trials only (in which one treatment group differed from another only by the beta-blocker therapy of interest) Randomization process precluded prior knowledge of the next treatment (for example trials in which treatment allocation was alternate or based on odd or even dates would not be included)  Trial sample size of less than 300 patients


eligible ages (years): 0.0-999.0,  All  Acromioclavicular Joint Dislocation Surgical Procedures, Operative Patient with Tossy grade 3 AC-dislocation was recruited between the years 1989 and 1991 at Kuopio University Hospital for a randomized controlled study A written informed consent  Not written informed consent


eligible ages (years): 0.0-17.0,  All  Congenital Heart Disease Infants or children (newborn to 17 years of age) undergoing cardiopulmonary bypass for elective surgical correction of a congenital heart defect Patients must be taking an ACE inhibitor prior to their operation  Patients in which discontinuing ACEIs is deemed unsafe by their primary cardiologist Any condition rendering the subjects legal guardian unable to understand the nature, scope, and possible consequences of the study Pregnancy as ruled out by standard of care screening procedures Individuals whose weight is less than 3.5 kg at the time of enrollment Inability to comply with the protocol. ie. Children in whom it is deemed unsafe to have the extra blood draws, and children who are thought to be noncompliant with their medications


eligible ages (years): 19.0-55.0,  All  Low Back Pain between the age of 19 and 55 years old able to walk without assistance and /or assistive devices at least 4.7 meters have adequate hearing acuity to detect verbal instructions have adequate visual acuity to walk safely in usual ambient lighting without holding onto objects be able to speak and comprehend English have sufficient cognitive ability to follow instructions, and to provide informed consent, as defined by a Mini Mental Status Examination score of greater than 23 out of 30, performed by the research coordinator  have had neurological signs and symptoms, or complications such as tumor or infection are active in a claim pertaining to a motor vehicle accident or work injury or under any litigation for their pain have had previous osteopathic treatment in the last year had more than one abdominal surgery, or spinal fracture, or structural deformity such as scoliosis or spondylolithesis (Hubley-Kozey, 2002) have severe cardiopulmonary disease as determined by a health questionnaire with symptoms such as shortness of breath or chest pain on mild exertion or at rest history of severe neurological disorder that impairs balance and mobility eg stroke, Parkinson's disease, peripheral neuropathy have pain that leads to severe discomfort with minimal movement have significant musculoskeletal impairment e.g. arthritis that leads to severe discomfort with walking that could lead to an abnormal gait have cognitive compromise impairing ability to care for oneself, and ability to provide informed consent have dizziness while standing


eligible ages (years): 18.0-999.0,  All  Malignant Pleural Effusion Pleural Effusion Clinically confident diagnosis of malignant pleural effusion requiring pleurodesis. The diagnosis may be established by one of Histologically proven pleural malignancy OR Typical features of pleural malignancy seen on direct vision during thoracoscopy OR Pleural effusion in the context of histologically proven cancer elsewhere Expected survival more than 1 month Written informed consent  Age < 18 years Primary lymphoma or small cell lung carcinoma Patients who are pregnant or lactating Inability to give informed consent History of GI bleeding or of untreated peptic ulceration Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)/opiates/acetaminophen Hypercapnic respiratory failure Known intravenous drug abuse Severe renal or liver disease Known bleeding diathesis


eligible ages (years): 21.0-999.0,  All  Diabetes Mellitus, Type 2 Type 2 diabetes for more than 1 year before study entry  Insulin therapy Treatment with any beta-blocker in the 30 days before study entry Asthma Chronic obstructive pulmonary disease (COPD) Greater than first degree heart block Heart rate less than 60 bpm Systolic blood pressure less than 90 mm Hg Raynaud's phenomenon Known history of angina, heart attack, heart failure, coronary revascularization, or automatic implantable cardioverter defibrillators Pregnant


eligible ages (years): 18.0-999.0,  All  Hypertension Patients over 18 years of age Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg) Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation) for the control arm (treated by ACEi) Patients over 18 years of age Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg) Patients, who tolerate ACEi treatment  Cholestasis, severe hepatic insufficiency Allergy to telmisartan Gravidity or lactation for the arm of patient treated by ACEi Cholestasis, severe hepatic insufficiency Allergy to ACEi Gravidity or lactation


eligible ages (years): 20.0-49.0,  All  Low Back Pain Healthy 49 years old Pregnant with a singleton Low back pain began during pregnancy and has lasted more than one week Low back pain is reproducible with palpation  Health conditions such as hypertension, diabetes, cancer, thyroid condition etc Pain radiates below knee Cannot read English Plans to move away from Portland area during pregnancy Not willing to be randomized to one of the three arms of the study


eligible ages (years): 2.0-999.0,  All  Sickle Cell Disease for the Observational and Trial Cohorts Hemoglobin diagnosis of SS (two copies of the hemoglobin S gene), SC (one copy of the hemoglobin S gene and one copy of the hemoglobin C gene), or S-β thalassemia (β+ or β0) No clinically apparent ACS No prior participation in either part of the study for the Trial Cohort, in addition to the above sPLA2 level greater than 100 ng/mL within the same 24-hour window that coincides with fever and chest radiograph negative for new pulmonary infiltrate within the last 12 hours of the 24-hour window Fever greater than 38.0º C within the same 24-hour window that coincides with elevated sPLA2 level (greater than 100 ng/mL) and chest radiograph negative for new pulmonary infiltrate within the last 12 hours of the 24-hour window Chest radiograph negative for new pulmonary infiltrate within the last 12 hours of the 24-hour window of an abnormal sPLA2 level and fever Hemoglobin levels equal or less than 10 g/dL at time of study entry Informed consent of parent(s) or legal guardian; informed consent or assent of participant as applicable  for Observational and Trial Cohorts Existing diagnosis of a new pulmonary infiltrate diagnosed by chest radiography (pleural effusion not obscuring lung parenchyma will not the person from the study) Any coexisting medical condition for which the physician feels that a transfusion may be needed within 24 hours (e.g., severe anemia, stroke) Red Blood Cell (RBC) transfusion in the 60 days before study entry Unwillingness to sign consent form, or if a minor, unwillingness of parent/guardian to sign consent form Treatment with any investigational drug or device in the 30 days before study entry (hydroxyurea is allowable) History of alloimmunization that would prevent the participant from receiving blood within 8 hours of for study entry or history of a life-threatening transfusion reaction Objection to transfusion for religious or other reasons from either the participant or guardian History of treatment with systemic steroids within 1 week of study entry (inhaled steroids are acceptable) Pregnant


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndromes The subject must be 18 years of age or older The subject must present to the Emergency Department with symptoms consistent with acute coronary syndromes (e.g., chest discomfort/pain, squeezing/fullness in the chest, pain radiating to left or both arms, jaw pain, pain in the back/neck/stomach, shortness of breath, cold sweat, nausea/vomiting, lightheadedness) The subject must present to the Emergency Department within 6 hours of the onset of the most recent symptoms that prompted the subject to seek medical attention in the Emergency Department The patient agrees to abide by all aspects of the protocol, including all telephone follow-up  The patient is unable to provide consent or understand the consent form The ACS symptoms are clearly not the result of ACS (i.e., penetrating wounds, crush injury, etc.)


eligible ages (years): 7.0-13.0,  All  Obesity Children enrolled in the MEND Programme who are yet to be given a start date for the programme Aged between 7-13 years old Overweight or obese as defined by a BMI which falls above the 91st centile on the boys/girls BMI chart UK cross-sectional reference data:1997/1) Clinically well with no known chronic illness  Age less than 7 years or older than 13 Known chronic illness


eligible ages (years): 30.0-75.0,  All  Ischemic Heart Disease Patients with intermediate (>20%, <90%) risk of IHD based on age,gender,symptoms and exercise stress test results  Age < 30 Yrs or > 75 yrs Pregnancy (suspected or ascertained) LV Dysfunction (LVEF < 35% by Echo or other method) Low (< =20%) or high (>=90%) probability of CAD Acute Coronary Syndrome Prolonged (> 20 minutes) chest pain De novo or accelerated angina Hemodynamic or electrical instability Recent ST-T segment or T wave changes of ischemic nature Acute myocardial infarction with or without ST segment elevation


eligible ages (years): 18.0-999.0,  All  Pain Back Pain Low Back Pain Back Pain With Radiation At Visit 1 (study entry) patients must have a medical history and physical and neurological examinations that support a clinical diagnosis of acute low back pain that is felt down to the lower leg below the knee with the onset no longer than 30 days before Visit 1 At Visit 1 patients must report qualifying pain intensity scores Patients must be appropriate candidates for treatment with oral opioid pain medication in the investigator's clinical judgment Patients must be able to appropriately verbalize pain characteristics and to complete all protocol required measurements/assessments without assistance Patients must be medically stable on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening  History of back (cervical, thoracic or lumbosacral) pain =50% of the time in the 1 year prior to the first visit History of any low back pain episode, with the exception of the current acute low back pain episode, within 3 months prior to the first visit that was greater than mild in pain intensity, or was associated with disability (e.g., loss of time from work, family, or activities of daily living), or necessitated the use of an opioid (narcotic) analgesic including tramadol Medical history or physical examination results that suggest the acute low back pain or any of the neurological symptoms or signs are caused by a serious medical condition (e.g., fever, chills, unexplained weight loss, bowel or urinary bladder dysfunction or incontinence, bilateral leg weakness, progressive weakness, paralysis) There is a high probability for surgical intervention for the back pain during the projected time on the study or that there will be an increase in the severity of the leg pain or deficits Had either a surgical procedure involving the spine or intervertebral discs in the lower back region within 1 year prior to Visit 1 or had >1 surgical procedure(s) involving the spine or intervertebral discs in the lower back region has any painful condition that could interfere with the study assessments or with the patient's ability to differentiate the pain associated with the acute low back pain episode from pain associated with another condition History of severe lumbar spinal stenosis, fibromyalgia, or ankylosing spondylitis history of epilepsy or recurrent seizures Unable or unwilling to discontinue all prohibited medications at the time of randomization and during the time of their participation in the study Known or suspected history of alcohol or drug abuse based on medical history, physical examination, urine drug screening, or the investigator's clinical judgment


eligible ages (years): 20.0-90.0,  All  Adhesive Capsulitis shoulder discomfort for at least one month limited range of motion of the glenohumeral joint in at least two directions  systemic inflammatory joint disease radiological evidence of bony abnormality of the shoulder full-thickness rotator cuff tear acute systemic medical illness history of major trauma or surgery involving the shoulder contraindication to intra-articular, local anesthestic injection


eligible ages (years): 20.0-75.0,  All  Obstructive Sleep Apnea Hypertension Apnea and hypopnea index of more than 20 /hr, and treated with CPAP Uncontrolled hypertension (defined as systolic blood pressure of more than 130 mmHg or diastolic blood pressure of more than 80 mmHg  Cerebrovascular diseases, myocardial infarction, angina pectoris or heart failure within 6 months Uncontrolled arrhythmia Severe hepatic or renal disorders Having poor prognosis disorders such as malignant disorders


eligible ages (years): 18.0-80.0,  All  Resistant Hypertension NIDDM 80 years, informed consent, hypertension, type-II-diabetes mellitus  Non-compliance, s-creatinin above 200, AFli


eligible ages (years): 18.0-999.0,  All  Atherosclerosis Over 18 years old CCT > 60 ml/min No IHD No hyper/hypoparathyroidism No active malignancy Not taking calcium, phosphate  Under 18 years of age Not fulfilling


eligible ages (years): 18.0-999.0,  All  ST Segment Elevation Acute Coronary Syndrome The decision to randomise patients must be made by a qualified physician or paramedic who is present at the time Subjects may be included in the study if they present either via ambulance or to a centre where PCI is not performed and meet all of the following Provide written informed consent before initiation of any study related procedures. Patients randomised in the ambulance may initially sign an abridged version Be aged ≥18 years at the time of randomisation Have a presumed diagnosis of a STE-ACS with onset of symptoms of >20 minutes and <12 hours with one or more of the following ST segment elevation of ≥1 mm in ≥2 contiguous leads Presumably new left bundle branch block An infero-lateral MI with ST segment depression of ≥1 mm in ≥2 of leads V1-3) with a positive terminal T wave All patients must be scheduled for angiography +/ PCI (if indicated) <2 hours after first medical contact  Subjects will be excluded from the study if any of the following apply prior to randomisation Any bleeding diathesis or severe haematological disease or history of intra-cerebral mass, aneurysm, arterio-venous malformation, haemorrhagic stroke, intra-cranial haemorrhage or gastrointestinal or genitourinary bleeding within the last 2-weeks Patients who have undergone recent surgery (including biopsy) within the last two weeks Patients on warfarin (not applicable if INR known to be <1.5) Patients who have received UFH, LMWH or bivalirudin immediately before randomisation Thrombolytic therapy within the last 48 hours Absolute contraindications or allergy that cannot be pre-medicated to iodinated contrast or to any of the study medications including aspirin or clopidogrel Contraindications to angiography, including but not limited to severe peripheral vascular disease If it is known pregnant or nursing mothers. Women of child-bearing age will be asked if they are pregnant or think that they may be pregnant


eligible ages (years): 10.0-999.0,  All  Allergic Conjunctivitis Positive bilateral conjunctival allergen challenge(CAC) reaction  Known contraindications or sensitivities to the study medication or its components Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters Use of disallowed medications during the period indicated prior to study enrollment or during the study


eligible ages (years): 30.0-80.0,  All  Stable Angina Stable angina patients whose coronary lesions is confirmed by angiography or receives PCI Unstable Angina/NSTEMI patients who completed PCI for main lesions Either systolic > 130mmHg or diastolic > 80mmHg, or patients with anti-hypertensive drugs  STEMI patients within one month Variant Angina Liver function abnormality or renal failure History of Hypersensitivity to testing drugs Severe heart failure(NYHA class>3) or uncorrectable hematologic disease Woman possible to be pregnant Uncontrolled diabetes Expected life span < one year


eligible ages (years): 19.0-55.0,  All  Healthy Overweight Obesity Subjects with BMI over 25.0 kg/m2 Non-smoker  Excessive alcohol consumption Pregnant or lactating women Dyslipidemia, hyperglycemia, or other chronic diseases Subjects who were taking vitamin supplements


eligible ages (years): 18.0-75.0,  All  Acute Coronary Syndrome Coronary Artery Disease Diagnosis of unstable angina and non-Q wave myocardial infarction Age 18-75 yr Diameter stenosis of coronary artery<70% diameter stenosis by visual estimation Blood pressure >110/70 mmHg Heart rate 60-~100 bpm, No cardiac arrhythmias  St-elevation myocardial infarction Lower blood pressure(<100/70mmHg) Heart rate <60 or >100 bpm, The presence of cardiac arrhythmias Allergy to study drugs Women in pregnancy Liver dysfunction Creatinine >2.5mg/dl Bleeding stroke within 6 months Left ventricular ejection fraction<30% before maximal medication


eligible ages (years): 18.0-60.0,  All  Abdominoplasty Bilateral Breast Reduction Bilateral Breast Lift Bilateral Brachioplasty Bilateral Lateral Thigh and Buttocks Lift Subject is >18 years of age or < 60 years old Subject is undergoing abdominoplasty, bilateral breast reduction, bilateral breast lift, bilateral brachioplasty, bilateral lateral thigh and buttocks lift, or any combination thereof Subject is able to discontinue anticoagulant therapy (including Aspirin) Subject is willing and able to comply with study follow-up procedures Subject is willing to provide written informed consent for their participation in the study  Subject has a history of smoking in the last 6 months prior to surgery Subject has a history of type I or type II Diabetes Subject has an active infection of any kind at the time of enrollment Subject has a known coagulopathy


eligible ages (years): 18.0-999.0,  All  Ischemic Heart Disease ischemic heart disease patient, and given loading or maintenance dose of clopidogrel and in need of it for 1 or more month and in need of additional drug for optimal BP control (aim blood pressure <130/90) or angina control  existing use of amlodipine thrombocytopenia end stage renal failure allergy to clopidogrel/ amlodipine pregnancy/ lactation strong inhibitor or inducer of cytochrome P450 3A4 enzyme within 7 days before start of the study


eligible ages (years): 18.0-999.0,  All  Hypertension hypertension age > 18 ACE-I related cough  Current treatment with telmisartan Cholestatic disorders and severe hepatic failure Allergy to telmisartan Pregnancy and lactation period


eligible ages (years): 18.0-999.0,  All  Head and Neck Neoplasms Laryngeal Neoplasms Mouth Neoplasms Pharyngeal Neoplasms Histologically confirmed squamous cell carcinoma (with biopsy on the primary and / or lymph node metastases) of the oral cavity, oropharynx, hypopharynx, larynx supraglottix Locally advanced disease, defined by one of the following any T, N +, M0 (excluding T1, N1), T3-4, N0, M0 Not cancer nasopharynx or paranasal sinuses or salivary glands General conditions and associated diseases which does not allow to perform chemotherapy or radiotherapy in a radical view No other surgical treatments, chemotherapy or radiotherapy for cancer of head and neck or elsewhere, except non-melanoma skin cancer or in situ cervical cancer and other solid tumors for which radical treatment has been completed > three years prior to enrollment in the study and for which the patient has remained continuously free of disease Accessibility to follow-up Signing of informed consent Interval between examinations of local staging and randomization, maximum 3 weeks Interval between randomization and initiation of treatment, maximum 2 weeks  Age <18 years ECOG performance status > 0-1 Hemoglobin <9 g / dL Counts of granulocytes, total <1.5 x 10 ^ 9 / L Platelet count <100 x 10 ^ 9 / L Bilirubin> 1.5 times upper limit of normal (ULN) AST or ALT> 3 times ULN Creatinine clearance > 50 mL/min Mg > 0.5 mmol/L Pregnancy or lactation


eligible ages (years): 18.0-999.0,  All  Acute Renal Failure all ICU patients requiring renal replacement therapy  patient denies informed consent patient not requiring intensive care therapy kidney transplanted patients chronic renal failure (serum creatinine > 3mg/dl)


eligible ages (years): 35.0-75.0,  All  Coronary Heart Disease Male or female; age 35-75 years having angina (Canada Cardiovascular Society Class II-IV) Essential Hypertension defined as taking at least 1 anti-hypertensive medication, or average systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mmHg ST-T changes of LVH (Romhilt-Estes or Framingham Heart Study with typical LV strain pattern, or isoelectric, inverted or biphasic T waves) ST-T changes of ischemia in resting ECG (ST depression, isoelectric, biphasic, negative or inverted T-waves) Serum potassium < 5.0 mmol/L prior to randomization Negative pregnancy test in child-bearing potential women Willing to comply with scheduled visits Informed consent form signed by the subject  Resistance hypertension despite 3-drugs treatment Myocardial infarction in past 90 days Coronary artery bypass graft surgery in past 90 days Atrial fibrillation with a resting heart rate > 90 bpm Percutaneous coronary intervention in past 30 days Implanted Pacemaker Stroke in past 90 days Left or Right Ventricular Branch Block Aldosterone antagonist or K sparing drug in last 7 days Intolerance to amiloride


eligible ages (years): 60.0-85.0,  All  Low Back Pain Obesity chronic low back pain for >6 months >3 pain episodes per week waist circumferences ≥102 cm for men waist circumferences ≥ 88 cm for women willing and able to participate in regular exercise for 14 weeks using pain medications to control low back pain free of abnormal cardiovascular responses during a screening graded maximal walk test  unable to walk participating in regular resistance exercise training (>3X week) in the past 6 months pain symptoms are too severe and prevent strength testing or walking acute back injury spinal stenosis that precludes walking one block due to neurogenic claudication back surgery within the past 2 years current use of weight loss interventions (drugs; exercise interventions)


eligible ages (years): 0.0-70.0,  All  Ischemic Heart Disease Obesity obesity Ischemic Heart disease Signed informed consent  Visual or manual limitations that preclude reading and writing Unwilling to participate


eligible ages (years): 18.0-999.0,  All  Ovarian Cancer Subjects who aged 18 years or older Subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial Subjects who have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning is required to evaluate resectability. Measurable disease is not required  Subjects who have received prior radiation therapy (XRT) for pancreatic cancer unless progression was documented after XRT and 6 weeks have elapsed between completion of XRT and start of trial medication Subjects who have had systemic treatment such as chemotherapy or immunotherapy, for pancreatic cancer. However, prior use of chemotherapy, e.g. 5-FU or capecitabine, for radiation sensitization is allowed. If gemcitabine was given in the adjuvant setting, only subjects relapsed with cancer after 6 months of completing the last dose of gemcitabine can participate in the trial Subjects who have had a major surgery within 2 weeks prior to the screening/baseline visit


eligible ages (years): 18.0-80.0,  All  Functional Chest Pain Age 18 to 80, male or female Patients must fulfill the Rome III for Functional Chest Pain of Presumed Esophageal Origin for the previous 3 months (with symptom onset at least 6 months before diagnosis), including all of the following Midline chest pain or discomfort that is not of burning quality Absence of evidence that gastroesophageal reflux is the cause of the symptom Absence of histopathology-based esophageal motility disorders Persistent symptoms despite a trial of antidepressant therapy, as defined by either chest pain despite at least a continuous 4-week trial of at least one antidepressant within the last 6 months; or intolerance of at least one antidepressant within the last 6 months Negative cardiac evaluation (negative cardiac stress test or negative coronary angiogram) Negative gastrointestinal evaluation for cause of the pain, defined by absence of Los Angeles grade C or D erosive esophagitis on endoscopy, persistent chest pain on PPI therapy, and no association of chest pain with reflux episodes on an ambulatory pH or pH-impedance study, defined as a symptom index <50% or symptom association probability <95% for chest pain   Severe co-morbid illness (cardiac, pulmonary, renal, hematologic, hepatic) Prior treatment with hypnosis/hypnotherapy for a medical condition Prior major thoracic surgery Prior diagnosis of or treatment for dissociative disorders, post-traumatic stress disorder, borderline personality disorder, or other psychiatric disorders that psychotic features Pregnancy or planned pregnancy within the upcoming 3 months Inability or unwillingness to give informed consent


eligible ages (years): 18.0-999.0,  All  Atherosclerosis Major Men Obese BMI>30 No aspirin treatment before Coronary exploration: coronary angiography or tomography coronary angiography Chest pain like stable angina  Women Severe hepatic insufficiency Inflammatory disease Neoplasia Protein S deficiency Aspirin treatment 10 days before Oral anticoagulant treatment at Heparin or low molecular weight heparin treatment at


eligible ages (years): 18.0-999.0,  All  Cystic Fibrosis Back Pain Neck Pain Chest Pain Diagnosis of cystic fibrosis ( positive sweat test and / or presence of 2 disease causing mutations in the CFTR gene Age > 18 years Patient with chronic chest , neck or back pain Written Informed Consent with health insurance  regular follow-up by an osteopathic physician in the previous 3 months patients awaiting lung transplantation history of lung transplantation pregnancy understanding disorders preventing the patient to apply the study participation in another clinical interventional study protocol


eligible ages (years): 10.0-999.0,  All  Allergic Conjunctivitis Positive bilateral conjunctival allergen challenge (CAC) reaction  Known contraindications or sensitivities to the study medication or its components Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters Use of disallowed medications during the period indicated prior to the study enrollment or during the study


eligible ages (years): 18.0-79.0,  All  Angina Pectoris Coronary Artery Disease Type 2 Diabetes Mellitus Written informed consent Males and females aged 18 to 79 years Able to perform a Sheffield Modified Bruce Treadmill Exercise Protocol At least a 3-months history of chronic stable angina triggered by physical effort and relieved by rest and/or sublingual nitroglycerin Coronary artery disease documented by one or more of the following Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries History of myocardial infarction (MI) documented by positive CK-MB enzymes, troponins, or ECG changes Cardiac nuclear scan studies diagnostic of CAD, e.g., thallium scan or ECHO with stress or pharmacologic interventions (adenosine, dipyridamole, etc.) Stable treatment with one of the following antianginal medications for at least 4 weeks prior to Screening beta-blocker (atenolol up to 50 mg daily or metoprolol up to 100 mg daily)  Inability to exercise or having exercise limitation due to other co-morbidities that may interfere with ability to perform required ETT (e.g., morbid obesity, significant chronic lung disease, prior hospitalization for acute exacerbation of chronic lung disease or home oxygen use, chronic oral steroid therapy that can limit exercise capacity, osteoarthritis, peripheral artery disease, etc.) Any absolute contraindication to ETT Presence of electrocardiographic or other abnormalities that interfere with ECG interpretation or may cause a false positive stress test (e.g., ≥ 1 mm horizontal or down-sloping ST segment depression at rest in any standard ECG lead, Lown-Ganong-Levine syndrome, Wolff-Parkinson-White syndrome, left bundle branch block, left ventricular hypertrophy with repolarization abnormality, ventricular pacemaker, etc.) Decompensated heart failure Clinically significant valvular heart disease or congenital cardiac defects Acute coronary syndrome in the prior 2 months or coronary revascularization within the prior 6 months or planned coronary revascularization during the study period Stroke or transient ischemic attack within 6 months prior to Screening History of serious ventricular dysrhythmias or a history of life-threatening ventricular arrhythmia Atrial fibrillation QTc > 0.5 seconds


eligible ages (years): 18.0-75.0,  All  Asthma, Chronic Obstructive Pulmonary Disease (COPD) documented diagnosis of asthma or COPD in accordance with guidelines stable condition, defined as a disease without exacerbation for at least 1 month prior to study enrolment mean HR in holter ECG recording of ≥ 60 bpm  disease exacerbation in previous month inability to understand instructions on study procedures


eligible ages (years): 25.0-65.0,  All  Chronic Stable Angina Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes Male and female Age 25 to 65 years Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards Patient must be able to give voluntary written informed consent  Hypertension of > 170/100 mm of Hg Valvular heart disease and cardiomyopathy Myocardial infarction in < 6 months Unstable angina Congestive cardiac failure Severe anemia (Hb 7G/dl) Cardiac arrhythmias or II or III degree AV block Significant liver or renal dysfunction IDDM (Type-1 diabetes mellitus) Systolic blood pressure < 100 mm Hg


eligible ages (years): 21.0-999.0,  All  Acute Myocardial Infarction Heart Attack Acute Coronary Syndrome Unstable Angina Acute myocardial infarction, acute coronary syndrome, unstable angina, men & women, all races & ethnicities  age < 21 years


eligible ages (years): 18.0-50.0,  All  Obesity Subject, male or female, is age 18 to 50 years of age Subject must be able to understand and be willing to sign an informed consent document Subject must be willing and able to participate in all aspects of the study and agree to comply with all study requirements for the duration of the study. This includes availability of reliable transportation and sufficient time to attend all follow-up visits Subject has a BMI of 40 or 30 to 39.9 plus one or more co-morbid diseases expected to improve with weight loss, including but not limited to hypertension, dyslipidemia, obstructive sleep apnea, or diabetes mellitus Subject must be fully ambulatory, without chronic reliance on walking aids such as crutches, walkers or a wheelchair Subject must be of sufficient and stable medical health, as evaluated by the Principal Investigator Subject must have a primary care physician that will manage the subject for any co-morbid conditions throughout the study Subject must have failed standard obesity therapy of diet, exercise, behavior modification, and pharmacologic agents either alone or in combination, as assessed by an interview with a member of the study team at baseline Subject agrees to refrain from any type of reconstructive surgery that may affect body weight such as mammoplasty or abdominal lipoplasty or liposuction, during the trial  Subject has history of/or signs and/or symptoms of gastro-duodenal ulcer disease Subject has poorly controlled diabetes as indicated by the lack of stable diabetes medications and doses over the last month, or has a history of diabetes for greater than 10 years Subject has had significant weight loss in the last 3 months, or between baseline and the study procedure Subject has a history or is diagnosed with eating disorders Subject has history of peptic ulcer and tests positive for H. pylori, unless treated before the procedure Subject has symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease Subject has pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or cancer Subject has significant esophageal disease including Zenker's diverticulum, grade 3-4 reflux esophagitis, stricture, Barrett's esophagus, esophageal cancer, esophageal diverticulum, dysphagia, achalasia, or symptoms of dysmotility Subject is observed during EGD to have heavily scarred, malignant or poor quality/friable tissue in areas of the stomach where plications are to be placed


eligible ages (years): 25.0-50.0,  All  Hypertension essential hypertension ACE inhibitors  diabetes mellitus endocrinopathies no smokers


eligible ages (years): 18.0-999.0,  All  Breast Cancer TRIAL Patient age 18 years or older who self-identifies as African-American In early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancer Receiving health care primarily through an health maintenance organization (HMO) Patients with metastatic cancer or a second primary cancer, because their medical characteristics (e.g. disease progression) are significantly different Breast cancer survivors (BCS) with other major disabling medical, psychiatric, or substance abuse conditions (e.g., anxiety, depression, alcohol/tobacco problems) will be excluded PEER At least 25 years of age who self-identifies as African-American Previously participated in any type of research study Has at least high school education


eligible ages (years): 20.0-999.0,  All  Chronic Stable Angina Male or female aged > 20 Patients who had effort-induced angina which was relieved by rest or nitroglycerin, or who had catheterization-documented coronary artery disease or previous myocardial infarction ≥ 3 months before screening Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) at screening (Day -7) Patients who manifested positive ETT (exercise tolerance testing) (defined as ST-segment depression ≥ 1 mm compared with at rest, with or without limiting angina) on the day of enrollment (Day 0). ETT performance between Day -7 and Day 0 were required not differ by >20% in total exercise time Female patient who was in the post-menopausal stage or of childbearing potential who used adequate contraception since last menstruation and no plan for conception during the study was non-lactating had negative pregnancy test (urine) within 14 days prior to the study Able to provide written informed consent  Patients with pre-excitation, conduction abnormalities, pacemaker rhythm, unstable angina or myocardial infarction within the preceding 3 months Patients with heart failure (New York Heart Association class III or IV), uncorrected valvular or congenital heart disease, patients who needed digoxin, isosorbide mononitrate, nitroglycerin sustained release preparation, theophylline, class I antiarrhythmic agents, digitalis, or monoamine oxidase inhibitors, as judged by the investigator Patients with any EKG abnormalities preventing the interpretation of ischemia (complete left bundle branch block) Patients with Chronic Obstructive Pulmonary Disease (COPD) requiring bronchodilators Patients with hepatic failure (defined as aspartate transaminase (AST) and/or alanine transaminase (ALT) > 3X the upper limit of normal values), and/or renal failure (defined as serum creatinine > 3 mg/dL) Patients with severe gastrointestinal illness as judged by the investigator Patient with any conditions that interfered the performance of exercise tolerance test as judged by investigator (e.g., knee/ankle arthropathy, Parkinsonism, stroke)


eligible ages (years): 18.0-75.0,  All  Acute Coronary Syndrome Age 18 years Ischemic discomfort (ie, ischemic chest pain or equivalent) at rest ≥20 minutes within previous 24 hours Any (new, presumably new, or old) LBBB on the prehospital (ambulance) or admission ECG Urgent coronary angiography (followed, when indicated, by PCI), ideally within 90 minutes after admission  all-comers design


eligible ages (years): 18.0-75.0,  All  Angina Pectoris Myocardial Infarction Coronary Disease Myocardial Ischemia Acute Coronary Syndrome Patients affected by history of IHD with a non-fatal evolution(angina or AMI as first manifestation),age at the onset of the disease (<50 o >60 years Patients with acute coronary syndrome as first manifestation of coronary disease, admitted to the coronary unit within 6 hours from the onset of symptoms  Age>75 Pregnancy Recent(< 6 months) cerebral ischemic attack Active cancer Inability to provide an informed consent


eligible ages (years): 18.0-65.0,  All  Low Back Pain unilateral pain near the sacroiliac joint that does not extend pass the knee positive result on 2 of 6 sacroiliac joint provocation tests compression test distraction test posterior shear test Gaenslens' test (left and right) sacral thrust test  current pregnancy or pregnancy in the last 6 months history of surgery to lumbar spine, pelvis, chest, abdomen history of congenital lumbar or pelvic anomalies any neurological signs in the lower extremity


eligible ages (years): 18.0-999.0,  All  Primary Open Angle Glaucoma Diagnosis of POAG Documented glaucomatous VF damage with mean defect (MD) > 3 dB Progressing glaucomatous damage justifying a DSCI Aged ≥18 years, of either sex Not more than 4 diopters spherical equivalent on the study eye Not more than 2 diopters cylinder equivalent on the study eye Have given written informed consent, prior to any investigational procedures  Corneal or conjunctival abnormality precluding contact lens adaptation Severe dry eye syndrome Patients with allergy to corneal anesthetic Patients with contraindications for silicone contact lens wear Patients not able to understand the character and individual consequences of the investigation Participation in other clinical research within the last 4 weeks


eligible ages (years): 18.0-45.0,  All  LUMBAR BACK PAIN PELVIC PAIN PREGNANCY Lower back pain and / or posterior pelvic pain when completing the interview. Gestational age greater than or equal to 12 weeks  Twin pregnancy. Medical restrictions on the exercise. Be doing physical therapy for the symptom of back pain and / or posterior pelvic


eligible ages (years): 18.0-999.0,  All  Inappropriate Sinus Tachycardia Inappropriate sinus tachycardia (HR >100 bpm at rest ECG and/or medium Holter ECG HR >90 bpm) Age > 18 years  Secondary causes of sinus tachycardia Structural heart diseases Postural orthostatic tachycardia syndrome Sinus nodal reentrant tachycardia Contraindications to beta-blockers Administration of beta-blockers, non-di-hydropiridinic calcium channels antagonists, class I and III anti-arrhythmic drugs or digitalis at the time of enrollment Age < 18 years Inability of giving informed consent


eligible ages (years): 18.0-75.0,  All  Metastatic Breast Cancer age>=18years Eastern Cooperative Oncology Group (ECOG) performance status (PS) <=2 and a life expectancy >= 12 weeks histological-proven, HER-2 negative measurable stage IV disease exposure to anthracyclines, taxanes either in the neoadjuvant/adjuvant or in the metastatic setting and had documented disease progression after the firstline or secondline treatment Patients previously treated with radiotherapy were eligible for the study, provided that measurable disease existed outside the radiation field At least 3 weeks from the prior chemotherapy or radiotherapy. At least 2 weeks from the prior endocrine therapy  Patients with active infection or other serious underlying medical conditions Patients had prior treatment with 5-FU infusion and/or oxaliplatin therapy Inadequate bone marrow, liver, renal, medullary, and cardiac functions Evidence of spinal cord compression or brain metastasis History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer Pregnant or lactating women Serious uncontrolled intercurrent infection History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding Serious non-bleeding wound, peptic ulcer or bone fracture Prior dihypopyrimidine dehydrogenase deficiency


eligible ages (years): 40.0-80.0,  All  Coronary Disease non-acute chest pain those who underwent CT calcium scoring availability of all relevant risk factor information  previous coronary disease i.e., myocardial infarction or revascularization


eligible ages (years): 18.0-60.0,  All  Kidney Calculi Well functioning kidney (serum creatinine <1.2 mg/dl) Solitary renal stone Size: 25 mm or less in the largest diameter  Contraindications to ESWL Previous surgical treatment of renal stones Congenital renal anomalies Pediatric patients (age <18 years) Patients with Diabetes or hypertension


eligible ages (years): 18.0-85.0,  All  Hypertension Diagnosis of severe hypertension must be made on the basis of current findings, medical history, and physical examination  Any serious medical condition that may adversely affect the patient's safety, limit the subject's ability to participate in the study, comply with follow-up requirements or impact the scientific integrity of the study


eligible ages (years): 18.0-50.0,  All  Pregnancy Related Anaesthesia Viable, singleton pregnancy ≥ 37 weeks gestation undergoing EL LSCS Low risk for post-partum hemorrhage, such as no proven abruptio placentae, placenta previa, multiple pregnancy, pre-eclampsia / gestational hypertension, previous PPH, obesity (based on BMI pre pregnancy which is ≥ 30 kg/m2), big baby Ability to provide informed consent  Emergency caesarean section Preterm Labour Grandmultipara Multiple Pregnancy Placenta Previa Previous PPH Maternal Obesity ( BMI pre pregnancy ≥ 30 kg/m2)) Have co-morbidity illness such as hypertension/pre-eclampsia, established cardiac diseases, history or evidence of liver, renal, vascular, or endocrine disease and bleeding disorder Contraindication to carbetocin and oxytocin Language Barrier


eligible ages (years): 45.0-75.0,  All  Ischemic Heart Disease Obesity Stable Ischemic Heart Disease BMI 28 kg/m2  Known Diabetes Mellitus Repeated Fasting plasma glucose ≥ 7 mmol/L or Hba1c > 7 % Severe or moderate valve disease Main stem stenosis Severe heart failure, Ejection Fraction < 35 % Physical or mental disability which are expected to prevent completion of intervention Severe Chronic obstructive Pulmonary Disease (COPD) (FEV1 < 50 % of expected) or asthma Active cancer Severe kidney (GFR < 40 ml/hour) or severe liver disease Severe ischemia or arrhythmias during exercise test


eligible ages (years): 16.0-999.0,  All  Chest Pain All patients over the age of 18 years presenting with the leading symptom of first time or recurrent acute chest pain in the emergency room of the Department of Internal Medicine, University Hospital of Zurich  Missing informed consent Cardiopulmonary unstable patients No self reported chest pain Recent thoracic surgery within1 year, inflammatory joint disease, fibromyalgia, cardiogenic shock


eligible ages (years): 10.0-50.0,  All  Breast Cancer Any woman who identifies as African American, Black, or African Currently nursing a baby Able and willing to sign written informed consent Willing to be contacted by study personnel for follow-up to determine whether a biopsy took place Willing to have her milk sample archived for future analyses  The woman does not consider herself to be of African American, Black, or African. These women may participate in the other ongoing Breast Milk Study at University of Massachusetts Unable to sign written Informed Consent or Assent Form Unwilling to be contacted by study personnel


eligible ages (years): 18.0-65.0,  All  Episodic Tension-Type Headache Male and female patients from 18 years onwards History of ETTH for at least one year. The number of days with such a headache is ≥2 per month Onset of TTH below 65 years of age At least 10 previous headache attacks fulfilling the following four Patients with headache attacks lasting from 30 minutes to 7 days At least two of the following pain characteristics are present Pressing or tightening (non-pulsating) quality Intensity of pain: moderate = unable to ignore (pain may inhibit, but does not prohibit activities) Bilateral location No aggravation by walking stairs or similar routine physical activity  Headaches other than TTH: (e.g. migraine, cluster headache, hypertension headache, drug-related headache,analgesic-induced headache,post-traumatic headache; associated migraine attacks are permitted if they are well recognized by the patient and if their frequency during the preceding year has not exceeded one per month) Presence of oromandibular dysfunction History of facial or cranial surgery Use of prophylactic drugs for headache within one month prior to enrolment Use of drugs for acute TTH treatment for ≥ 10 days of headache per month Anticipated problems in adhering to the self-observation procedure (e.g. because of work) Abuse of alcohol, narcotics or other drugs Serious illnesses within the last 3 months (e.g. myocardial infarction, cardiac insufficiency NYHA III and IV, low blood pressure, cerebral insult, diabetes mellitus, neuropathy, changes in the skin or neoplasms in the head) Epilepsy Intake of anti-psychotic, anti-depressant or anti-epileptic medication during the previous month


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndrome Female (post menopausal or surgically sterile) and/or male aged 18 years or older Presenting with ACS fulfilling the following Symptoms or new ECG changes (ST segment elevation or depression of at least 1 mm in 2 or more contiguous leads on EKG) Elevation of biomarkers (CK-MB ≥2 ULN or troponin ≥ ULN) Self-identified as African-American Treatment with 75-100mg ASA daily  Any indication (atrial fibrillation, mitral stenosis or prosthetic heart valve, PE, DVT) for antithrombotic treatment during study period Fibrinolytic therapy within 48 hours before randomization Concomitant therapy with a drug having possible interaction with ticagrelor. (concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer) Increased bleeding risk including: recent (<30 days) GI bleeding, any history of intracranial, intraocular, retroperitoneal, or spinal bleeding, recent (<30 days of dosing) major trauma, sustained uncontrolled hypertension (systolic blood pressure [SBP]>180mmHg or diastolic blood pressure [DBP]>100mmHg), history of hemorrhagic disorders that can increase the risk of bleeding, platelet count less than 100,000 mm3 or hemoglobin <10 g/dL Any history of hemorrhagic stroke Contraindication or other reason that ASA or ticagrelor should not be administered (e.g., hypersensitivity, active bleeding, major surgery within 30 days of dosing) Severe renal failure (creatinine clearance <30mL/min or patient requires dialysis) History of moderate or severe hepatic impairment with aspartate amino transferace, alanine amino transferase or total bilirubin > 1.5 x upper limit of the reference range Pregnant or lactating women Patients receiving any glycoprotein IIb/IIIa inhibitors <8 hours before platelet reactivity testing


eligible ages (years): 18.0-999.0,  All  Back Pain Low Back Pain Neuropathic Pain Informed consent signed Male or female 18 years of age or older Women of childbearing potential must have a negative pregnancy test at the Enrollment Visit Women of childbearing potential must practice medically acceptable methods of birth control during the trial Participant must be appropriately communicative and able to differentiate with regard to location and intensity of the pain, and to complete the questionnaires used in this trial Participants must have a diagnosis of chronic low back pain; chronic pain defined as pain lasting for at least 3 months prior to enrollment Participant's pain must require a strong analgesic (defined as World Health Organization Step III) as judged by the investigator Participants who require a washout of co-analgesics at enrolment must have an average pain score (NRS-3) of 5 points or higher. Participants who do not require a washout of co-analgesics at enrollment must have an average pain intensity score (NRS-3) during the last 3 days of 6 points or higher The painDETECT diagnostic screening questionnaire must be either "positive" (score of 19 to 38 inclusive) or "unclear" (score of 13 to 18 inclusive). If the participant is being treated with a stable regimen of centrally acting co-analgesics, a "negative" painDETECT score (score 9 points or higher) prior to allocation to treatment  Presence of a clinically significant disease or clinical laboratory values that in the investigator's opinion may affect effectiveness, quality of life, or safety/tolerability assessments Presence of active systemic or local infections that may, in the opinion of the investigator, affect the effectiveness, quality of life, or safety/tolerability assessments Employees of the investigator or trial site, with direct involvement in this trial or other trials under the direction of the investigator or trial site, as well as family members of employees of the investigator Participation in another trial concurrently, or within 4 weeks prior to the Enrollment Visit Known to or suspected of not being able to comply with the protocol and/or appropriate use of the Investigational Medicinal Products Any painful procedures (e.g., major surgery) scheduled during the trial duration (Enrollment Visit until Final Evaluation Visit) that may, in the opinion of the investigator, affect the effectiveness, quality of life, or safety assessments Pending litigation or application for insurance/governmental benefits due to chronic pain or disability and/or if the granted benefits might be influenced by a successful participation in the trial Low back pain caused by cancer and/or metastatic diseases History of alcohol or drug abuse, or suspicion thereof in the investigator's judgment Presence of concomitant autoimmune inflammatory conditions


eligible ages (years): 18.0-80.0,  All  Pulmonary Arterial Hypertension Signed informed consent prior to any study-mandated procedure Patients with PAH who completed study AC-055-401 Women of childbearing potential must Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum pregnancy tests Agree to use two methods of contraception from Visit 1 until 1 month after study drug discontinuation  Patients who prematurely discontinued study drug in study AC-055-401 Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study Known hypersensitivity to macitentan or its excipients or drugs of the same class


eligible ages (years): 40.0-70.0,  All  Left Ventriclar Mass They had to have normal glucose tolerance They had to have either angiographically documented coronary artery disease or a previous history of myocardial infarction They were required to have an office BP < 130/80 mm Hg The presence of LVH on echocardiography (American Society of Echocardiography LVM index [LVMI] > 115 g/m2 for men and > 95 g/m2 for women)  They were currently prescribed metformin They had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women


eligible ages (years): 18.0-70.0,  All  Primary Hypertension Hypertension, Resistant to Conventional Therapy Essential hypertension subjects, aged 18-70 years, blood pressure > 140/90 mm Hg even used to be on 3 or more medications for a month and diagnosed as Phlegm and Stasis Syndrome will be included  Patients will be excluded for the following conditions: with secondary resistant hypertension because of other disease like renal disease or pheochromocytoma; included in other clinical trial in one month; pregnant or breast-feed or preparing for pregnancy female; combined with disease like stroke, coronary atherosclerotic heart disease, diabetes, chronic renal failure or mental disease


eligible ages (years): 18.0-999.0,  All  Acute Coronary Syndrome Provision of subject informed consent Patients hospitalized and diagnosed with STEMI or Hospitalized within 24 hours of onset of symptoms or transferred from another hospital within 24 hours of the onset of symptoms  STEMI and precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI STEMI and occurring in patients already hospitalized for other reasons Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances)